NCT02364362View on ClinicalTrials.gov

A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
DRUG

famitinib L + docetaxel

famitinib 15mg qd + docetaxel 60 mg/m\^2

DRUG

famitinib M + docetaxel

famitinib 20mg qd + docetaxel 60 mg/m\^2

DRUG

famitinib H + docetaxel

famitinib 25mg qd + docetaxel 60 mg/m\^2

Trial Locations (1)

200433

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT02364362 - A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter